Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
girocitinib
- Development stage
- Phase 3
- Lead developer
- Hangzhou Highlightll Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Girocitinib** (TLL-018) is an oral small molecule Janus kinase inhibitor developed by Hangzhou Highlightll Pharmaceutical, primarily targeting JAK1 and TYK2 to suppress pro-inflammatory JAK/STAT signaling pathways implicated in autoimmune and inflammatory diseases. It demonstrates potent inhibition with favorable selectivity (>40-fold JAK1 over JAK2), good pharmacokinetic properties, and is being evaluated for immune-mediated conditions including rheumatoid arthritis, chronic spontaneous urticaria, plaque psoriasis, and others.
- Brand names
- Girocitinib
- Other names
- TLL-018TLL018TLL 018
02
Targets
TYK2 (Tyrosine kinase 2)JAK1 (Janus kinase 1)
Beyond the preview
Go deeper on girocitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on girocitinib.